Travere Therapeutics (TVTX) Receivables (2014 - 2026)
Travere Therapeutics (TVTX) posted Receivables of $88.5 million for Q1 2026, up 8.68% on a QoQ basis from $81.4 million in Q4 2025, and up 142.47% year-over-year from $36.5 million in Q1 2025.
Travere Therapeutics (TVTX) Receivables (2014 - 2026) Analysis & Trends
Travere Therapeutics' Receivables history runs 13 years deep, the most recent figure standing at $88.5 million for Q1 2026.
- Quarterly Receivables rose 142.47% year-over-year to $88.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.5 million (up 142.47% YoY) and the FY2025 annual result came in at $81.4 million, up 176.84% from the prior year.
- Receivables was $88.5 million for Q1 2026 at Travere Therapeutics, up from $81.4 million in the prior quarter.
- Across five years, Receivables topped out at $88.5 million in Q1 2026 and bottomed at $12.7 million in Q3 2022.
- A 5-year average of $35.0 million and a median of $26.5 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables decreased 5.22% — and 2025, when it surged 205.05%.
- Travere Therapeutics' Receivables stood at $18.5 million in 2022, then surged by 39.0% to $25.8 million in 2023, then climbed by 14.11% to $29.4 million in 2024, then jumped by 176.84% to $81.4 million in 2025, then rose by 8.68% to $88.5 million in 2026.
- Business Quant data shows TVTX's Receivables at $88.5 million in Q1 2026, $81.4 million in Q4 2025, and $84.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | 88.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.50 Mn |
| Dec 31, 2025 | 81.43 Mn |
| Sep 30, 2025 | 84.50 Mn |
| Jun 30, 2025 | 40.22 Mn |
| Mar 31, 2025 | 36.50 Mn |
| Dec 31, 2024 | 29.42 Mn |
| Sep 30, 2024 | 27.70 Mn |
| Jun 30, 2024 | 27.27 Mn |
| Mar 31, 2024 | 26.53 Mn |
| Dec 31, 2023 | 25.78 Mn |
| Sep 30, 2023 | 18.70 Mn |
| Jun 30, 2023 | 22.90 Mn |
| Mar 31, 2023 | 23.54 Mn |
| Dec 31, 2022 | 18.55 Mn |
| Sep 30, 2022 | 12.70 Mn |
| Jun 30, 2022 | 16.69 Mn |
| Mar 31, 2022 | 14.70 Mn |
| Dec 31, 2021 | 16.81 Mn |
| Sep 30, 2021 | 13.40 Mn |
| Jun 30, 2021 | 11.90 Mn |